These contrasting results highlight the context-dependent impact of ferroportin inhibition; while beneficial in non-infectious anemias, restricting iron release during malaria may enhance parasite growth and worsen outcomes by increasing intracellular iron availability. Here, SLC40A1 is linked to malaria.